In vitro method to evaluate virus competition between BVDV-1 and BVDV-2 strains using the PrimeFlow RNA assay

Bovine viral diarrhea viruses (BVDV), segregated in BVDV-1 and BVDV-2 species, lead to substantial economic losses to the cattle industry worldwide. It has been hypothesized that there could be differences in level of replication, pathogenesis and tissue tropism between BVDV-1 and BVDV-2 strains. Thus, this study developed an in vitro method to evaluate virus competition between BVDV-1 and BVDV-2 strains. To this end the competitive dynamics of BVDV-1a, BVDV-1b, and BVDV-2a strains in cell cultures was evaluated by a PrimeFlow RNA assay. Similar results were observed in this study, as was observed in an earlier in vivo transmission study. Competitive exclusion was observed as the BVDV-2a strains dominated and excluded the BVDV-1a and BVDV-1b strains. The in vitro model developed can be used to identify viral variations that result in differences in frequency of subgenotypes detected in the field, vaccine failure, pathogenesis, and strain dependent variation in immune responses

Perfil genotípico e antigênico de amostras do vírus da diarréia viral bovina isoladas no Rio Grande do Sul (2000-2010)

Isolados do vírus da diarréia viral bovina (BVDV) apresentam grande diversidade genética e antigênica, o que pode dificultar o diagnóstico e a formulação de vacinas. O presente trabalho apresenta um perfil genotípico e antigênico de 20 amostras do BVDV isoladas no Estado do Rio Grande do Sul entre 2000 e 2010. As amostras foram oriundas de uma variedade de condições clínicas, que incluíam doença respiratória ou gastroentérica aguda ou crônica, lesões cutâneas, abortos, animais com crescimento retardado, além de animais persistentemente infectados (PI). A maioria das amostras (19 ou 95%) pertence ao biótipo não-citopático (NCP); enquanto um isolado apresentou uma mistura de vírus NCP e citopático (CP). O sequenciamento e análise filogenética de uma região de 270 nucleotídeos da região 5' não-traduzida do genoma viral permitiu identificar 9 isolados de BVDV-2 (45%) e 8 isolados de BVDV-2 (40%). Três amostras não agruparam filogeneticamente com nenhum dos genótipos, sendo classificados como pestivírus atípicos. Não foi possível associar os genótipos ou subgenótipos com as condições clínicas e, tanto os BVDV-1 quanto os BVDV-2 estavam envolvidos em diferentes síndromes clínico-patológicas. Análise de reatividade com um painel de 19 anticorpos monoclonais (AcMs) revelou uma variabilidade marcante na glicoproteína principal do envelope (E2) entre vírus do mesmo genótipo, e sobretudo, entre vírus de genótipos diferentes. Testes de neutralização viral (SN) com anti-soro de cepas de referência de BVDV-1 e BVDV-2 frente às amostras isoladas revelaram níveis variáveis de reatividade cruzada entre vírus do mesmo genótipo, e reatividade muito baixa ou ausente entre vírus de genótipos diferentes. Esses resultados indicam uma frequência semelhante de BVDV-1 e BVDV-2 na população estudada, confirmam a marcante variabilidade antigênica e reforçam a necessidade de se incluir vírus dos dois genótipos nas vacinas. Finalmente, indicam a presença de pestivírus atípicos circulantes na população bovina do RS

Antibody titers to vaccination are not predictive of level of protection against a BVDV type 1b challenge in Bos indicus - Bos taurus steers

AbstractSubclinical illness associated with infection is thought to reduce performance and increase production costs in feedlot cattle, but underlying components remain largely unidentified. Vaccination is frequently used in feedlot settings but producers lack metrics that evaluate the effectiveness of vaccination programs. The goal of this study was to determine if levels of serum neutralizing antibody titers were predictive of levels of vaccine protection in a commercial setting. During this four-year study, Angus-Nellore steers housed in a production feedlot setting were assigned to 1 of 3 vaccine treatments: killed vaccine (kV), modified live virus (MLV) vaccine, or no vaccine (control), and were challenged with a noncytopathic 1b field strain of bovine viral diarrhea virus. Rectal temperature and levels of circulating lymphocytes and platelets were monitored following challenge. While no animals were diagnosed as clinically ill with respiratory disease, indicators of disease (pyrexia, lymphopenia, and thrombocytopenia) were observed. The MLV treatment elicited higher antibody titers to the vaccination than the kV, and calves in the MLV treatment had higher mean titers at challenge. The year that elicited the highest antibody response to the vaccination and the year with the lowest frequency of phenotypic responses to the challenge were not concurrent. The MLV treatment had the highest proportion, 34.68%, of animals that were protected against the challenge regardless of the pre-challenge antibody titer and had the fewest number of lymphopenia cases in response to the challenge. Both vaccine treatments mitigated thrombocytopenia when compared to the control treatment, and the MLV treatment reduced lymphopenia; however, these symptoms were not completely eliminated in vaccinated animals. Pyrexia was present in 40.11% of the animals, but no difference in the frequency of cases between treatments was observed. Pre-challenge vaccination response was not indicative of the level of protection nor was anamnestic antibody response correlated with health status